Display options
Cite
Kadouh NK, Lang S, Shamoun M, et al. Mexiletine: An adjuvant option for refractory pain in patients with sickle cell disease and comorbid autism spectrum disorder. Pediatr Blood Cancer. 2021;e29526doi: 10.1002/pbc.29526.
Kadouh, N. K., Lang, S., Shamoun, M., Scott, E. L., Singh, S. A., & Smith, M. A. (2021). Mexiletine: An adjuvant option for refractory pain in patients with sickle cell disease and comorbid autism spectrum disorder. Pediatric blood & cancer, e29526. https://doi.org/10.1002/pbc.29526
Kadouh, Nour K, et al. "Mexiletine: An adjuvant option for refractory pain in patients with sickle cell disease and comorbid autism spectrum disorder." Pediatric blood & cancer vol. (2021): e29526. doi: https://doi.org/10.1002/pbc.29526
Kadouh NK, Lang S, Shamoun M, Scott EL, Singh SA, Smith MA. Mexiletine: An adjuvant option for refractory pain in patients with sickle cell disease and comorbid autism spectrum disorder. Pediatr Blood Cancer. 2021 Dec 28;e29526. doi: 10.1002/pbc.29526. Epub 2021 Dec 28. PMID: 34962695.
Copy Download .nbib Format: NLM
Share it on

Pediatr Blood Cancer. 2021 Dec 28;e29526. doi: 10.1002/pbc.29526. Epub 2021 Dec 28.

Mexiletine: An adjuvant option for refractory pain in patients with sickle cell disease and comorbid autism spectrum disorder.

Pediatric blood & cancer

Nour K Kadouh, Stacy Lang, Mark Shamoun, Eric L Scott, Sharon A Singh, Michael A Smith

Affiliations

  1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
  2. Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  3. Departments of Pediatrics and Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan, USA.

PMID: 34962695 DOI: 10.1002/pbc.29526

[No abstract available.]

Publication Types